We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement
News

Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement

Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement
News

Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Myriad Genetics, Inc. announced that it has signed an agreement with Pharma Mar, a leader in the development of marine-derived drugs. Under the agreement, Myriad will conduct BRCA 1 and BRCA 2 testing on patients to be enrolled in a Phase II clinical study of PM1183, a novel drug candidate which induces double-stranded DNA breaks to cause cell death.

"PM1183 is an exciting compound, and we are extremely pleased to be working with Pharma Mar on this project," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "We believe this agreement, as well as our many other companion diagnostic projects for DNA-damaging agents, demonstrates the importance of a patient's BRCA status in identifying potential responders to this class of drugs."

Under the agreement, Myriad will assess the BRCA status in patients who respond to PM1183. Myriad has entered into similar agreements with Abbott Pharmaceuticals, Astra Zeneca, BioMarin Pharmaceuticals and Cephalon to provide companion diagnostic testing with the BRACAnalysis(R) test for clinical trial enrollment.

Advertisement